| Identification | Back Directory | [Name]
LOBAPLATIN | [CAS]
135558-11-1 | [Synonyms]
d19466
Lobaplatin (D-19466)
Platinum,[rel-(1R,2R)-1,2-cyclobutanedimethanamine-kN,kN'][(2S)-2-(hydroxy-kO)propanoato(2-)-kO]-, (SP-4-3)- (9CI)
Platinum, [rel-(1R,2R)-1,2-cyclobutanedimethanamine-.kappa.N,.kappa.N'][(2S)-2-(hydroxy-.kappa.O)propanoato(2-)-.kappa.O]-, (SP-4-3)- (9CI) (CA INDEX NAME) | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C9H18N2O3Pt | [MDL Number]
MFCD00866545 | [MOL File]
135558-11-1.mol | [Molecular Weight]
397.33 |
| Chemical Properties | Back Directory | [Melting point ]
220° (dec) | [storage temp. ]
Store at -20°C | [solubility ]
Water: ≥ 50 mg/mL (125.84 mM; DMSO can inactivate Lobaplatin's activity) | [form ]
Solid | [color ]
White to off-white | [Water Solubility ]
Water: ≥ 50 mg/mL (125.84 mM; DMSO can inactivate Lobaplatin's activity) |
| Hazard Information | Back Directory | [Biological Activity]
Lobaplatin (D-19466) is a third-generation platinum anticancer agent in vitro and in vivoconsisting of ~50:50 mixture of the two trans-1,2-cyclobutanedimethanamine diastereomers in complex with L-lactic acid. Llobaplatin shows antitumor efficacy against various human cancer cancer xenografts and significantly prolongs the survival of mice bearing P388 leukemia (mean life span increase post single i.p. in mg/kg = 46%/4.64 & 77/14.7). Compared to first and second generation platinum compoundslobaplatin appears to be more stableless toxichave a better therapeutic index and may overcome tumor resistance. |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
Candia Thamtech Company Limited
|
| Tel: |
0371-86615086 18203638366 0371-86159066 13526786601 |
| Website: |
m.is0513.com/ShowSupplierProductsList15771/0.htm |
|